Clinical Trial Update: Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating the long-term safety and efficacy of SPN-812 (viloxazine extended-release) for attention-deficit/hyperactivity disorder; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QELBREE (viloxazine hydrochloride)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 3 | Status: ACTIVE_NOT_RECRUITING